Sze Marc A, Utokaparch Soraya, Elliott W Mark, Hogg James C, Hegele Richard G
Departments of Medicine and Pathology and Laboratory Medicine, Centre for Heart Lung Innovation, Providence Heart-Lung Institute at St Paul's Hospital, University of British Columbia, Vancouver, British Columbia, Canada.
Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada.
BMJ Open. 2015 Feb 4;5(2):e006677. doi: 10.1136/bmjopen-2014-006677.
The present study assesses the relationship between contents of GD1 (glycerol dehydratase)-positive Lactobacillus, presence of Lactobacillus and the inflammatory response measured in host lung tissue in mild to moderate chronic obstructive pulmonary disease (COPD). We hypothesise that there will be a loss of GD1 producing Lactobacillus with increasing severity of COPD and that GD1 has anti-inflammatory properties.
Secondary care, 1 participating centre in Vancouver, British Columbia, Canada.
74 individuals who donated non-cancerous portions of their lungs or lobes removed as treatment for lung cancer (normal lung function controls (n=28), persons with mild (GOLD 1) (n=21) and moderate (GOLD 2) COPD (n=25)).
Primary outcome measure was GD1 positivity within each group and whether or not this impacted quantitative histological measures of lung inflammation. Secondary outcome measures included Lactobacillus presence and quantification, and quantitative histological measurements of inflammation and remodelling in early COPD.
Total bacterial count (p>0.05) and prevalence of Lactobacillus (p>0.05) did not differ between groups. However, the GD1 gene was detected more frequently in the controls (14%) than in either mild (5%) or moderate (0%) COPD (p<0.05) samples. Macrophage and neutrophil volume fractions (0.012±0.005 (mean±SD) vs 0.026±0.017 and 0.005±0.002 vs 0.015±0.014, respectively) in peripheral lung tissue were reduced in samples positive for the GD1 gene (p<0.0035).
A reduction in GD1 positivity is associated with an increased tissue immune inflammatory response in early stage COPD. There is potential for Lactobacillus to be used as a possible therapeutic, however, validation of these results need to be completed before an anti-inflammatory role of Lactobacillus in COPD can be confirmed.
本研究评估了轻度至中度慢性阻塞性肺疾病(COPD)患者中,GD1(甘油脱水酶)阳性乳酸杆菌含量、乳酸杆菌的存在与宿主肺组织炎症反应之间的关系。我们假设,随着COPD严重程度的增加,产生GD1的乳酸杆菌数量会减少,且GD1具有抗炎特性。
二级医疗保健机构,加拿大不列颠哥伦比亚省温哥华的1个参与中心。
74名捐赠了因肺癌治疗而切除的肺或肺叶非癌部分的个体(正常肺功能对照组(n = 28)、轻度(GOLD 1)(n = 21)和中度(GOLD 2)COPD患者(n = 25))。
主要观察指标是每组内GD1阳性情况以及这是否影响肺炎症的定量组织学测量。次要观察指标包括乳酸杆菌的存在与定量,以及早期COPD中炎症和重塑的定量组织学测量。
各组之间的总细菌计数(p>0.05)和乳酸杆菌患病率(p>0.05)没有差异。然而,在对照组(14%)中检测到GD1基因的频率高于轻度(5%)或中度(0%)COPD患者(p<0.05)的样本。GD1基因阳性样本的外周肺组织中巨噬细胞和中性粒细胞体积分数分别降低(分别为0.012±0.005(平均值±标准差)对0.026±0.017和0.005±0.002对0.015±0.014)(p<0.0035)。
在早期COPD中,GD1阳性率降低与组织免疫炎症反应增加有关。乳酸杆菌有作为一种可能治疗方法的潜力,然而,在确认乳酸杆菌在COPD中的抗炎作用之前,需要完成这些结果的验证。